10:34 AM EDT, 08/21/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) shares fell 2.7% in early trading Wednesday after the company reported blood sugar reductions of up to 2.50% in its ongoing animal study on GLP-1 diabetes treatments.

At 56 days, DehydraTECH-liraglutide and two DehydraTECH-CBD formulations showed the highest blood sugar reductions of 2.50%, 1.90%, and 1.53%, respectively, the company said.

Lexaria said the findings suggest a potential for DehydraTECH-CBD in diabetic control, especially when combined with GLP-1 drugs.

Price: 3.16, Change: -0.09, Percent Change: -2.74